N-(naphthalen-2-ylmethyl)pentan-3-amine | 1042512-10-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-(naphthalen-2-ylmethyl)pentan-3-amine
• CAS: 1042512-10-6
• 化学式: C₁₆H₂₁N
• mdl: MFCD11121325
• 分子量: 227.349
• InChiKey: IIKFJUPSROFAGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-(naphthalen-2-ylmethyl)pentan-3-amine 、 2,4-二氯苯甲酰氯 在 4-二甲氨基吡啶 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 以13 mg的产率得到2,4-dichloro-N-(naphthalen-2-ylmethyl)-N-(pentan-3-yl)benzamide
  参考文献：
  名称：

  Structure–activity relationships of small molecule inhibitors of RAGE-Aβ binding

  摘要：

  The Receptor for Advanced Glycation Endproducts ('RAGE') mediates transport of amyloid-beta peptide (A beta) into the brain, and is therefore an important target for the development of therapeutic agents for Alzheimer's disease. We describe structure activity relationships for inhibition of RAGE-A beta binding, derived from the analysis of a library of tertiary amides. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2013.05.079
• 作为产物：
  描述：

  2-萘甲醛 、 3-氨基戊烷 在 sodium cyanoborohydride 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 8.0h， 以100%的产率得到N-(naphthalen-2-ylmethyl)pentan-3-amine
  参考文献：
  名称：

  Structure–activity relationships of small molecule inhibitors of RAGE-Aβ binding

  摘要：

  The Receptor for Advanced Glycation Endproducts ('RAGE') mediates transport of amyloid-beta peptide (A beta) into the brain, and is therefore an important target for the development of therapeutic agents for Alzheimer's disease. We describe structure activity relationships for inhibition of RAGE-A beta binding, derived from the analysis of a library of tertiary amides. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2013.05.079

文献信息

• Spirocyclic compounds as tryptophan hydroxylase inhibitors
  申请人：Roivant Sciences GmbH

  公开号：US10350208B2

  公开（公告）日：2019-07-16

  The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

  本发明涉及的螺环化合物是色氨酸羟化酶（TPH），特别是同工酶 1（TPH1）的抑制剂，可用于治疗与外周血清素相关的疾病或失调，例如包括胃肠道、心血管、肺、炎症、代谢和低骨量疾病，以及血清素综合征和癌症。
• SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS
  申请人：Roivant Sciences GmbH

  公开号：US20180092918A1

  公开（公告）日：2018-04-05

  The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.